Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Obsessive-compulsive disorder (OCD) is a debilitating mental health condition.
• Serotonin pathways are implicated in OCD pathophysiology.
• 5-HT3 antagonists are a class of drugs that target serotonin receptors.

Purpose of the Study:

• To review and evaluate the efficacy and safety of 5-HT3 antagonists in treating OCD.
• To compare clinical findings with preclinical data from animal models.

Main Methods:

• Literature search of the PubMed database for studies on 5-HT3 antagonists and OCD.
• Inclusion of human clinical trials and animal models of OCD.

Main Results:

• Ondansetron and granisetron, 5-HT3 receptor antagonists, demonstrated some efficacy in OCD treatment across multiple studies.
• Both drugs showed superiority to placebo in double-blind trials with a fair safety profile.
• No current animal models of OCD directly implicate 5-HT3 receptors.

Conclusions:

• 5-HT3 antagonists show potential utility in managing OCD symptoms.
• The existing literature is insufficient for definitive conclusions due to limited data.
• A discrepancy exists between animal models and clinical data for 5-HT3 antagonists in OCD, requiring further investigation.